< Back to Newsroom

MultiCell Technologies Announces a New Class of Patented Therapeutics Eradicates Disease and Prevents Death in Animal Studies -- Targets Multibillion Dollar Worldwide Market for Immune Disorders and Cancer SAN DIEGO, March 21, 2007 (PRIME NEWSWIRE) -- MultiCell Technologies, Inc. (OTC BB:MCET.OB - News), developing first-in-class drugs based on advanced immune system modulation technologies, has announced its patented recombinant immunoglobulin peptide (IgP) technology creates a highly specific and superior antibody therapeutic. MultiCell's patented IgP antibody therapeutics are a new class of human antibody therapeutics engineered using recombinant DNA technology to contain disease-associated, T-cell responsive, therapeutic peptides. MultiCell's IgP antibody therapeutics have shown a superior ability to more specifically target key immune system regulators, and elicit cytokine production compared to traditionally administered peptide therapeutics. In preclinical animal models for relapsing-remitting multiple sclerosis and juvenile diabetes, MultiCell's IgP antibody therapeutics eradicated the disease and prevented death in the treated population, while all of the control animals died as a result of the disease. In preclinical animal models, MultiCell's IgP antibody therapeutics have been shown to eradicate cancer and prevent recurrence when co-administered with MCT-465, MultiCell's Toll-like receptor (TLR) agonist. ``When a person's T-cells are activated in autoimmune disease, they produce antibodies which attack specific targets such as pancreatic islet cells, or the protective myelin sheath surrounding nerves resulting in diabetes or multiple sclerosis,'' explained Dr. Stephen Chang, President and CEO of MultiCell Technologies. ``Our IgP antibody therapeutics contain T-cell responsive therapeutic peptides that bind only to the autoimmune disease-producing T-cells, causing the cells to self destruct and the disease to be eradicated,'' added Dr. Chang. ``In cancer, our IgP antibody therapeutics work synergistically with our TLR agonist, MCT-465, to kill tumor cells by immune system activation, specific cellular targeting, and cell death,'' said Dr. Chang. ``In both autoimmune disease and cancer, our IgP antibody therapeutics prevent recurrence of the disease by sensitizing the immune system in a manner similar to how a vaccine immunizes against future attack.'' ``T-cells are only responsive to small peptides, so the antibody therapeutic must be engineered with the therapeutic peptide portion displayed in the most optimal location for maximum efficacy,'' stated Dr. Chang. ``Taken together, we believe we have developed the next-generation antibody therapeutic having the best attributes of today's therapeutic antibodies such as specificity and the ability to modulate the immune system. At the same time, our IgP antibody therapeutics minimize the short in vivo half-life and non-specific targeting of traditional peptide therapeutics.'' MultiCell is an innovator in the science of modulating the human immune system, focusing on the development of breakthrough drugs to treat serious diseases, including chronic fatigue-associated with multiple sclerosis, relapsing-remitting multiple sclerosis, juvenile diabetes, influenza, and cancer. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is based on modulation of the immune system. MultiCell's therapeutic pipeline includes: * MCT-125 a Phase IIb drug for the treatment of chronic fatigue in MS patients. * MCT-175 for the treatment of relapsing-remitting MS. * MCT-275 for the treatment of juvenile diabetes. * MCT-465 for the treatment of virus infection and cancer. * MCT-475 for the treatment of colorectal cancer. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the pharmaceutical industry to develop new drugs. For more information about MultiCell Technologies, please visit http://www.multicelltech.com. Caution Regarding Forward-Looking Statements Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the ``Act''). These statements are often, but not always, made through the use of words or phrases such as ``believe,'' ``will,'' ``expect,'' ``anticipate,'' ``estimate,'' ``intend,'' ``plan,'' ``forecast,'' ``could,'' and ``would.'' Examples of such forward-looking statements include statements regarding the timing, design, scope, and anticipated results of our clinical development programs. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our products as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2006, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and each assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events. Contact: MultiCell Technologies, Inc. Dr. Stephen Chang, 858.200.0598 MCETInvestor@MultiCelltech.com or SmallcapInsights.com Dr. John Faessel, 858-587-8590 editors@smallcapinsights.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul@trilogy-capital.com Source: PrimeNewswire (Wednesday March 21, 10:38 am ET)